Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  2002-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/JCEM.87.2.7980PMID 11836266
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.

  2000cited by this paper
• Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.

  2000cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

  2000cited by this paper
• Pharmacology of diuretics.

  2000cited by this paper
• Fibrinolytic function in diuretic-induced volume depletion.

  2000cited by this paper
• , Brigitte Angiotensin II Receptor Blockade and Role in Cardiac Fibrosis Activation of Cardiac Aldosterone Production in Rat Myocardial Infarction : Effect of

  1999cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Synergistic Effect of Adrenal Steroids and Angiotensin II on Plasminogen Activator Inhibitor-1 Production*

  1999cited by this paper
• Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

  1998cited by this paper
• Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1.

  1998influential reference
• Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats.

  1997cited by this paper
• Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.

  1996cited by this paper
• Magnesium therapy, fibrinolytic parameters and von Willebrand factor in acute myocardial infarction.

  1996cited by this paper
• Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV.

  1995cited by this paper
• Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension.

  1995cited by this paper
• Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.

  1995cited by this paper
• Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats.

  1994cited by this paper
• Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism.

  1993cited by this paper
• Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.

  1992cited by this paper
• Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

  1992cited by this paper
• Spironolactone, an aldosterone antagonist, acts as an antiglucocorticosteroid on the mouse mammary tumor virus promoter.

  1992cited by this paper
• Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension.

  1991cited by this paper
• Reassessment of plasma angiotensins measurement: effects of protease inhibitors and sample handling procedures.

  1991cited by this paper
• Circulating levels of angiotensin I measured by radioimmunoassay in hypertensive subjects.

  1979cited by this paper
• Downloaded from http://hyper.ahajournals.org / by guest on February 21, 2013Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats

  year unknowncited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Hormonal Control of Plasminogen Activator Inhibitor-1 Gene Expression and Production in Human Adipose Tissue: Stimulation by Glucocorticoids and

  year unknowncited by this paper

• Orchestra of ligand-activated transcription factors in the molecular symphony of SERPINE 1 / PAI-1 gene regulation.

  2024cites this paper
• The Effect of Aldosterone on Cardiorenal and Metabolic Systems

  2023cites this paper
• Effect of diuretics on plasma aldosterone and potassium in primary hypertension: A systematic review and meta‐analysis

  2021cites this paper
• The paradigm of norgestimate: a third-generation testosterone-derivative progestin with a peripheral anti-androgenic activity and the lowest risk of venous thromboembolism

  2021cites this paper
• Hyperglycemia Potentiates Prothrombotic Effect of Aldosterone in a Rat Arterial Thrombosis Model

  2021cites this paper
• Bioactive Molecules Derived from Snake Venoms with Therapeutic Potential for the Treatment of Thrombo-Cardiovascular Disorders Associated with COVID-19

  2021influential citation
• Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?

  2020cites this paper
• Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis

  2020cites this paper
• Pathogenesis and preventive approach of hypercoagulopathy and microvascular thrombosis induced mortality from COVID-19

  2020cites this paper
• Effect of diuretics on plasma renin activity in primary hypertension: A systematic review and meta‐analysis

  2020cites this paper
• Is spironolactone the preferred renin-angiotensin-aldosterone inhibitor for protection against COVID-19?

  2020cites this paper
• Effect of spironolactone for 1 yr on endothelial function and vascular inflammation biomarkers in renal transplant recipients

  2019cites this paper
• Potential Protective Role of Blood Pressure-Lowering Drugs on the Balance between Hemostasis and Fibrinolysis in Hypertensive Patients at Rest and During Exercise

  2019cites this paper
• The Aldosterone/Renin Ratio Predicts Cardiometabolic Disorders in Subjects Without Classic Primary Aldosteronism

  2019cites this paper
• University of Southern Denmark Effect of spironolactone for 1 yr on endothelial function and vascular inflammation biomarkers in renal transplant recipients

  2019cites this paper
• Vascular Mineralocorticoid Receptor: Evolutionary Mediator of Wound Healing Turned Harmful by Our Modern Lifestyle

  2018cites this paper
• Hormonal contraception: venous and arterial disease

  2017cites this paper
• Endocrine determinants of haemostasis and thrombosis risk: Focus on thyroid hormone

  2016cites this paper
• Effects of mineralocorticoid receptor antagonists on the risk of thrombosis, bleeding and mortality: A systematic review and meta-analysis of randomized controlled trials.

  2016cites this paper
• Mineralocorticoid receptor antagonists in dialysis patients

  2016cites this paper
• Aldosterone and cardiovascular disease: the heart of the matter.

  2013cites this paper
• Peptidergic regulation of plasminogen activator inhibitor‐1 gene expression in vivo

  2013cites this paper
• Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery*

  2012cites this paper
• Differential Effects of Nebivolol and Metoprolol on Insulin Sensitivity and Plasminogen Activator Inhibitor in the Metabolic Syndrome

  2012cites this paper
• Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study

  2011cites this paper
• Reducing cardiovascular Risk in patients Following MI with eplerenone

  2010cites this paper
• [Prothrombotic aldosterone action--a new side of the hormone].

  2010cites this paper
• Effect of combined angiotensin‐converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients

  2010cites this paper
• Choice of diuretic therapy and reconsideration for aldosterone receptors blockers.

  2010cites this paper
• Irbesartan and hydrochlorothiazide association in the treatment of hypertension.

  2009cites this paper
• Aldosterone activates endothelial exocytosis

  2009cites this paper
• The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas.

  2009cites this paper
• Aldosteronomas--state of the art.

  2009cites this paper
• Mineralocorticoid receptors in the metabolic syndrome.

  2009cites this paper
• Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial †

  2009cites this paper
• AldosteronomasçState of the Art

  2009cites this paper
• Hypertension and hemostatic/fibrinolytic balance disorders.

  2009cites this paper
• American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations.

  2009cites this paper
• Aldosterone as an Independent Factor in Cerebrovascular Damage

  2008cites this paper
• Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats.

  2008cites this paper
• Relationship of plasma renin with a prothrombotic state in hypertension: relevance for organ damage.

  2008cites this paper
• Effect of Renin-Angiotensin-Aldosterone System Triple Blockade on Non-Diabetic Renal Disease: Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker

  2008cites this paper
• Aldosterone and vascular inflammation.

  2008cites this paper
• Role of angiotensin and the clock system in the circadian regulation of plasminogen activator inhibitor-1.

  2008cites this paper
• Metabolic and Antihypertensive Effects of Combined Angiotensin Receptor Blocker and Diuretic Therapy in Prediabetic Hypertensive Patients With the Cardiometabolic Syndrome

  2008cites this paper
• A Dynamic Comparative Study Concerning the Effects of Angiotensin-Converting Enzyme Inhibitors and Aldosterone Receptor Blockers on the Fibrinolytic System

  2008cites this paper
• spontaneously hypertensive rats factors in kidney of adrenalectomized stroke-prone Aldosterone , but not angiotensin II , increases profibrotic

  2007cites this paper
• Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients

  2007cites this paper
• Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats.

  2007cites this paper
• [Molecular mechanism of cardiovascular damage induced by aldosterone].

  2007cites this paper
• Intracardiac and Intrarenal Renin-Angiotensin Systems

  2007cites this paper
• A Dynamic Comparative Study Concerning the Effects of ACE Inhibitors and Aldosterone Receptor Blockers on Fibrinolytic System

  2007cites this paper
• Aldosterone antagonists in heart failure

  2007cites this paper
• Jak diuretyki działają na ścianę naczyń krwionośnych — czy mamy nowe argumenty na rzecz stosowania dawno poznanych leków w nadciśnieniu tętniczym? Diuretics' influence on blood vessels — have we got new arguments promoting administration of diuretics in arterial hypertension?

  2007cites this paper
• Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism.

  2006cites this paper
• Aldosterone receptor antagonists for heart failure: current status, future indications.

  2006cites this paper
• Antihypertensive Drugs and Fibrinolytic Function: Impact of Dual Calcium Channel and Renin-Angiotensin System Blockade

  2006cites this paper
• Valsartan, Blood Pressure Reduction, and C-Reactive Protein: Primary Report of the Val-MARC Trial

  2006cites this paper
• Hospital protocols and evidence‐based therapies: The importance of integrating aldosterone blockade into the management of patients with post—acute myocardial infarction heart failure

  2006cites this paper
• Angiotensin II Induces Interleukin-6 in Humans Through a Mineralocorticoid Receptor–Dependent Mechanism

  2006cites this paper
• Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology.

  2006cites this paper
• Aldosterone antagonism in chronic kidney disease.

  2006cites this paper
• Antihypertensive drugs and fibrinolytic function.

  2006cites this paper
• Mechanisms of target organ damage caused by hypertension: therapeutic potential.

  2006cites this paper
• Chapter 75 – Adrenal Cortex Hypertension

  2005cites this paper
• Śródbłonkowe działanie aldosteronu - implikacje terapeutyczne płynące z badań podstawowych i klinicznych

  2005cites this paper
• Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes.

  2005cites this paper
• Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction

  2005cites this paper
• Melanocortin-4 Receptor–Deficient Mice Are Not Hypertensive or Salt-Sensitive Despite Obesity, Hyperinsulinemia, and Hyperleptinemia

  2005cites this paper
• Is the Effect of Antihypertensive Drugs on Platelet Aggregability and Fibrinolysis Clinically Relevant?

  2005cites this paper
• Regression of existing glomerulosclerosis by inhibition of aldosterone.

  2005cites this paper
• Angiotensin II and Vascular Extracellular Matrix

  2004cites this paper
• Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes.

  2004cites this paper
• Review of aldosterone- and angiotensin II-induced target organ damage and prevention.

  2004cites this paper
• Eplerenone: Will it have a role in the treatment of acute coronary syndromes?

  2004cites this paper
• Aldosterone resurgens--letter from EPHESUS.

  2003cites this paper
• Primary aldosteronism - treatment options.

  2003cites this paper
• Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease

  2003cites this paper
• Aldosterone: A risk factor for vascular disease

  2003cites this paper
• Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1.

  2003cites this paper
• Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease.

  2003cites this paper
• The effects of antihypertensive therapy on haemostatic parameters.

  2003cites this paper
• Aldosterone and Not Plasminogen Activator Inhibitor-1 Is a Critical Mediator of Early Angiotensin II/ NG-Nitro-l-Arginine Methyl Ester-Induced Myocardial Injury

  2003cites this paper
• Minireview: primary aldosteronism--changing concepts in diagnosis and treatment.

  2003cites this paper
• Resistance artery mechanics and composition in angiotensin II-infused rats: effects of aldosterone antagonism

  2003cites this paper
• Aldosterone in chronic kidney and cardiac disease.

  2003cites this paper
• DISEASE OF THE MONTH

  2003cites this paper
• Aldosterone Function in Diabetes Mellitus: Effects on Cardiovascular and Renal Disease

  2003cites this paper
• ACE Inhibition Versus Angiotensin Type 1 Receptor Antagonism: Differential Effects on PAI-1 Over Time

  2002cites this paper
• PAI-1 in human hypertension: relation to hypertensive groups.

  2002cites this paper
• Aldosterone--an independent risk factor in cardiovascular disease.

  2002cites this paper
• The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease.

  2002cites this paper
• Effect of Spironolactone on Impaired Fibrinolysis of Hypertensive Patients

  2002cites this paper